WO2011083141A3 - Panning phage libraries with lipoprotein particles expressing the target antigen - Google Patents

Panning phage libraries with lipoprotein particles expressing the target antigen Download PDF

Info

Publication number
WO2011083141A3
WO2011083141A3 PCT/EP2011/050157 EP2011050157W WO2011083141A3 WO 2011083141 A3 WO2011083141 A3 WO 2011083141A3 EP 2011050157 W EP2011050157 W EP 2011050157W WO 2011083141 A3 WO2011083141 A3 WO 2011083141A3
Authority
WO
Grant status
Application
Patent type
Prior art keywords
immunoglobulin sequences
lipoprotein particles
invention relates
target antigen
antigens
Prior art date
Application number
PCT/EP2011/050157
Other languages
French (fr)
Other versions
WO2011083141A2 (en )
Inventor
Maria Gonzalez Pajuelo
Guy Hermans
Peter Vanlandschoot
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

The present invention relates to a method for generating immunoglobulin sequences against cell-associated antigens, more particularly, antigens that are membrane-anchored. The invention also provides immunoglobulin sequences obtainable by the method of the invention. Specifically, the present invenlion relates to the generation of immunoglobulin sequences by using lipoprotein particles. More specifically, the present invention relates to generation of immunoglobulin sequences in camelids, preferably directed against cell-associated antigens, in particular antigens with multiple transmembrane spanning domains, including GPCRs and ion channels, by using lipoprotein particles. Furthermore, the invention relates to novel immunoglobulin sequences, constructs and uses thereof.
PCT/EP2011/050157 2010-01-08 2011-01-07 Panning phage libraries with lipoprotein particles expressing the target antigen WO2011083141A3 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US29329710 true 2010-01-08 2010-01-08
US61/293,297 2010-01-08

Publications (2)

Publication Number Publication Date
WO2011083141A2 true WO2011083141A2 (en) 2011-07-14
WO2011083141A3 true true WO2011083141A3 (en) 2011-09-22

Family

ID=43741414

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2011/050157 WO2011083141A3 (en) 2010-01-08 2011-01-07 Panning phage libraries with lipoprotein particles expressing the target antigen
PCT/EP2011/050156 WO2011083140A1 (en) 2010-01-08 2011-01-07 Immunoglobulin single variable domain directed against human cxcr4

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/050156 WO2011083140A1 (en) 2010-01-08 2011-01-07 Immunoglobulin single variable domain directed against human cxcr4

Country Status (1)

Country Link
WO (2) WO2011083141A3 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9328174B2 (en) * 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
EP2953973A1 (en) 2013-02-05 2015-12-16 VIB vzw Muscarinic acetylcholine receptor binding agents and uses thereof
WO2016156570A1 (en) * 2015-04-02 2016-10-06 Ablynx N.V. Bispecific cxcr4-cd-4 polypeptides with potent anti-hiv activity
EP3349787A2 (en) * 2015-09-18 2018-07-25 Arch Oncology, Inc. Therapeutic cd47 antibodies
WO2017220990A9 (en) 2016-06-20 2018-03-01 Kymab Limited Anti-pd-l1 antibodies

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183247A1 (en) * 1997-05-20 2002-12-05 The Trustees Of The University Of Pennsylvania Lipoparticle comprising a protein and methods of making and using the same
WO2005042695A2 (en) * 2003-07-30 2005-05-12 Integral Molecular, Inc. Lipoparticles comprising proteins, methods of making, and using the same
WO2009138519A1 (en) * 2008-05-16 2009-11-19 Ablynx Nv AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
WO2010070145A2 (en) * 2008-12-19 2010-06-24 Ablynx N.V. Method for generation of immunoglobulin sequences

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
EP1621554B2 (en) 1992-08-21 2012-08-29 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
ES2155854T3 (en) 1993-06-09 2001-06-01 Unilever Nv Method of producing fusion proteins comprising ScFv fragments with the help of a transformed mold.
FR2708622B1 (en) 1993-08-02 1997-04-18 Raymond Hamers recombinant vector containing a sequence of a structure of the lipoprotein gene for expression of nucleotide sequences.
US6091639A (en) 1993-08-27 2000-07-18 Kabushiki Kaisha Toshiba Non-volatile semiconductor memory device and data programming method
EP0759170B1 (en) 1993-09-10 2008-07-09 The Trustees Of Columbia University In The City Of New York Uses of green fluorescent protein
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
JPH10501681A (en) 1994-02-22 1998-02-17 ダナ−ファーバー キャンサー インスティチュート Nucleic acid delivery system as well as synthetic and using the same
US5625048A (en) 1994-11-10 1997-04-29 The Regents Of The University Of California Modified green fluorescent proteins
WO1996022307A1 (en) 1995-01-19 1996-07-25 The Research Foundation Of State University Of New York Genes encoding an insect calcium channel
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US5693492A (en) 1995-05-05 1997-12-02 Merck & Co., Inc. DNA encoding glutamate gated chloride channels
DE69604298D1 (en) 1995-09-22 1999-10-21 Novo Nordisk As Variants of the green fluorescent protein, gfp
US6027881A (en) 1996-05-08 2000-02-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Mutant Aequorea victoria fluorescent proteins having increased cellular fluorescence
DK0937140T3 (en) 1996-06-27 2008-01-28 Vlaams Interuniv Inst Biotech Antibody molecules that specifically interact with a target molecule active site or cleft
US6124128A (en) 1996-08-16 2000-09-26 The Regents Of The University Of California Long wavelength engineered fluorescent proteins
WO1998021355A1 (en) 1996-11-15 1998-05-22 Life Technologies, Inc. Mutants of green fluorescent protein
EP1051493A2 (en) 1998-01-26 2000-11-15 Unilever N.V. Method for producing antibody fragments
WO1999042077A3 (en) 1998-02-19 2004-05-27 Xcyte Therapies Inc Compositions and methods for regulating lymphocyte activation
WO1999047158A3 (en) 1998-03-13 1999-11-25 Univ British Columbia Therapeutic chemokine receptor antagonists
EP2311495B1 (en) 1998-03-24 2014-09-24 Chugai Seiyaku Kabushiki Kaisha Vascularization inhibitors
JP4786793B2 (en) 1998-03-30 2011-10-05 ノースウエスト バイオセラピューティクス,インコーポレイティド Therapeutic and diagnostic applications based on the role of CXCR-4 gene in tumorigenesis
GB9824632D0 (en) 1998-11-10 1999-01-06 Celltech Therapeutics Ltd Biological compounds
WO2000043507A1 (en) 1999-01-19 2000-07-27 Unilever Plc Method for producing antibody fragments
US5994285A (en) 1999-06-14 1999-11-30 Colgate-Palmolive Co. Liquid laundry detergent composition containing ethoxylated amine quaternary surfactant
GB9922124D0 (en) 1999-09-17 1999-11-17 Pfizer Ltd Phosphodiesterase enzymes
US6479280B1 (en) 1999-09-24 2002-11-12 Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
DE60031441D1 (en) 1999-11-29 2006-11-30 Unilever Nv Immobilization of proteins with the help of a polypeptide segment
WO2001044301A1 (en) 1999-11-29 2001-06-21 Unilever Plc Immobilized single domain antigen-binding molecules
ES2324280T3 (en) 2000-03-14 2009-08-04 Unilever N.V. Variable domains of the heavy chain antibodies to human dietary lipases and their uses.
WO2001090190A3 (en) 2000-05-26 2002-08-01 Ca Nat Research Council Single-domain antigen-binding antibody fragments derived from llama antibodies
WO2002057445A1 (en) 2000-05-26 2002-07-25 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
US6741957B1 (en) 2000-07-21 2004-05-25 Daimlerchrysler Corporation Analytical tire model for vehicle durability and ride comfort analysis
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
CN1911965B (en) 2001-01-17 2013-05-29 新兴产品开发西雅图有限公司 Binding domain-immunoglobulin fusion proteins
CA2440582A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
CA2447851C (en) 2001-06-28 2012-08-28 Domantis Limited Dual-specific ligand and its use
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
DE60305919D1 (en) 2002-06-28 2006-07-20 Domantis Ltd Cambridge Dual-specific ligand with an increased half-life
EP1425694A2 (en) 2001-08-03 2004-06-09 Medical Research Council Method of identifying a consensus sequence for intracellular antibodies
JP4213586B2 (en) 2001-09-13 2009-01-21 株式会社抗体研究所 A method for manufacturing a camel antibody library
JP2005289809A (en) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) Mutant heavy-chain antibody
KR100599789B1 (en) 2001-12-03 2006-07-12 삼성에스디아이 주식회사 Plasma display device with improved efficiency of radiating heat and manufacturing method therof
WO2003050531A3 (en) 2001-12-11 2004-03-18 Ablynx Nv Method for displaying loops from immunoglobulin domains in different contexts
CA2471116A1 (en) 2001-12-21 2003-07-03 Serge Muyldermans Method for cloning of variable domain sequences
CA2471645A1 (en) 2002-01-03 2003-07-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Immunoconjugates useful for treatment of tumours
EP1552827A4 (en) 2002-06-19 2006-08-30 Maruha Corp Oral preventive/therapeutic agent for skin damage containing diacylglyceryl ether
US7004940B2 (en) 2002-10-10 2006-02-28 Ethicon, Inc. Devices for performing thermal ablation having movable ultrasound transducers
EP2267027A3 (en) 2002-11-08 2011-07-20 Ablynx N.V. Method of administering therapeutic polypeptides, and polypeptides therefor
WO2004062551A3 (en) 2003-01-10 2004-09-02 Ablynx Nv RECOMBINANT VHH SINGLE DOMAIN ANTIBODY FROM CAMELIDAE AGAINST VON WILLEBRAND FACTOR (vWF) OR AGAINST COLLAGEN
WO2004041865A3 (en) 2002-11-08 2004-07-15 Ablynx Nv Stabilized single domain antibodies
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
US20060228355A1 (en) 2003-11-07 2006-10-12 Toon Laeremans Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
US20050279676A1 (en) 2004-06-21 2005-12-22 Izzy Zuhair A Fluid filter assembly for a dispensing faucet
US20060008601A1 (en) 2004-06-25 2006-01-12 Zeik Douglas B Flexible laminate having an integrated pressure release valve
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
JP5113523B2 (en) 2004-10-13 2013-01-09 アブリンクス ナームローゼ フェンノートシャップ Polypeptides comprising Nanobodies (TM) for the treatment of neurodegenerative diseases such as Nanobodies and Alzheimer's disease on amyloid -β
WO2006040154A3 (en) 2004-10-14 2006-08-17 Univ Dublin City Prokaryotic two hybrid system
CA2595682A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
EP2007814A2 (en) 2005-05-20 2008-12-31 Ablynx N.V. Single domain vhh antibodies against von willebrand factor
EP1934259A2 (en) 2005-10-11 2008-06-25 Ablynx N.V. Nanobodies and polypeptides against egfr and igf-ir
WO2007112940A3 (en) 2006-03-31 2008-01-03 Ablynx Nv Albumin-derived amino acid sequence, use thereof for increasing the half-life of therapeutic proteins and of other therapeutic compounds and entities, and constructs comprising the same
WO2008020079A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
US20100034194A1 (en) 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
US20100129368A9 (en) 2006-10-11 2010-05-27 Ablynx N.V. Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the pH, compounds comprising the same, and uses thereof
CA2671581A1 (en) 2006-12-05 2008-06-12 Ablynx N.V. Peptides capable of binding to serum proteins
EP2215123A1 (en) 2007-11-27 2010-08-11 Ablynx N.V. Immunoglobulin constructs
WO2009095235A1 (en) 2008-01-29 2009-08-06 Ablynx N.V. Methods to stabilize proteins and polypeptides
US9005963B2 (en) * 2008-10-14 2015-04-14 Ablynx N.V. Amino acid sequences directed against cellular receptors for viruses and bacteria
WO2010130832A3 (en) 2009-05-15 2011-04-21 Ablynx N.V. Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183247A1 (en) * 1997-05-20 2002-12-05 The Trustees Of The University Of Pennsylvania Lipoparticle comprising a protein and methods of making and using the same
WO2005042695A2 (en) * 2003-07-30 2005-05-12 Integral Molecular, Inc. Lipoparticles comprising proteins, methods of making, and using the same
WO2009138519A1 (en) * 2008-05-16 2009-11-19 Ablynx Nv AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
WO2010070145A2 (en) * 2008-12-19 2010-06-24 Ablynx N.V. Method for generation of immunoglobulin sequences

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Applications: The lipoparticle", 2008, XP002633841, Retrieved from the Internet <URL:http://replay.web.archive.org/20080923234222/http://www.integralmolecular.com/applications.asp> [retrieved on 20110420] *
ANONYMOUS: "Elicitation of Monoclonal Antibodies using Lipoparticles", 2009, XP002633842, Retrieved from the Internet <URL:http://www.integralmolecular.com/download/INTG-AN-Lipoparticle%20Immunogens.pdf> [retrieved on 20110420] *
ANONYMOUS: "Lipoparticles vs. Membrane Preparations", 2008, XP002638497, Retrieved from the Internet <URL:http://www.integralmolecular.com/download/INTG-AN-Membrane%20Prep%20Comparison.pdf> [retrieved on 20110420] *
CHOWDHURY PARTHA S: "DNA immunization as a means to generate antibodies to proteins.", METHODS IN MOLECULAR BIOLOGY (CLIFTON, N.J.), vol. 207, 2003, pages 57 - 62, XP009136819, ISSN: 1064-3745 *
DEFFAR KHALISSA ET AL: "Nanobodies - the new concept in antibody engineering", AFRICAN JOURNAL OF BIOTECHNOLOGY, vol. 8, no. 12, 17 June 2009 (2009-06-17), ACADEMIC PRESS, US, pages 2645 - 2652, XP009136924, ISSN: 1684-5315 *
KOCH-NOLTE FRIEDRICH ET AL: "Single domain antibodies from llama effectively and specifically block T cell ecto-ADP-ribosyltransferase ART2.2 in vivo.", THE FASEB JOURNAL : OFFICIAL PUBLICATION OF THE FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY, vol. 21, no. 13, November 2007 (2007-11-01), pages 3490 - 3498, XP002594033, ISSN: 1530-6860 *
WESOLOWSKI JANUSZ ET AL: "Single domain antibodies: promising experimental and therapeutic tools in infection and immunity", MEDICAL MICROBIOLOGY AND IMMUNOLOGY, vol. 198, no. 3, 1 August 2009 (2009-08-01), SPRINGER, BERLIN, DE, pages 157 - 174, XP009124313, ISSN: 1432-1831, [retrieved on 20090616], DOI: 10.1007/S00430-009-0116-7 *
WILLIS SHARON ET AL: "Virus-like particles as quantitative probes of membrane protein interactions.", BIOCHEMISTRY, vol. 47, no. 27, 8 July 2008 (2008-07-08), pages 6988 - 6990, XP002633843, ISSN: 1520-4995 *

Also Published As

Publication number Publication date Type
WO2011083140A1 (en) 2011-07-14 application
WO2011083141A2 (en) 2011-07-14 application

Similar Documents

Publication Publication Date Title
WO2008130551A3 (en) Antibiotic resistance free listeria strains and methods for constructing and using same
WO2009032782A3 (en) Compositions that bind multiple epitopes of igf-1r
Kim Sound scene control of multi-channel audio signals for realistic audio service in wired/wireless network
Sullivan Forming a Life of the Mind for Practice: Teaching Practical Reasoning
WO2008151146A3 (en) Peptide arrays and methods of use
Mead Biography: June Mead
WO2009130649A3 (en) Plasma membrane vesicles and methods of making and using same
GB2486479B (en) Apparatus for generating energy from waves
EP2666058B8 (en) Electrophotographic photoconductor, image forming method, image forming apparatus, and process cartridge
GB2505063B (en) Video conference bridge setting sharing, pushing, and rationalization
EP2613535A4 (en) Method for encoding and decoding video, and apparatus using same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11700039

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11700039

Country of ref document: EP

Kind code of ref document: A2